Literature DB >> 31153874

Pathophysiology and management of combined aortic and mitral regurgitation.

Philippe Unger1, Patrizio Lancellotti2, Mihaela Amzulescu3, Aurelia David-Cojocariu3, Didier de Cannière4.   

Abstract

The combination of aortic and mitral regurgitation is a typical example of a frequent yet understudied multiple valve disease scenario. The aetiology is often rheumatic or degenerative; less frequently it can be induced by drugs or radiation, or caused by infective endocarditis or congenital valvular lesions. Aortic regurgitation resulting in secondary mitral regurgitation is also not uncommon. There are limited data to guide the management of combined aortic and mitral regurgitation. Left ventricular dysfunction is frequent at initial presentation, and even more so postoperatively, suggesting that surgical management should not be delayed, particularly when symptoms occur or when there is evidence of even subtle left ventricular dysfunction. The decision to operate on one or both valves not only depends on the severity of each lesion, but also on several other factors, including age, co-morbidities and frailty, the increased operative risk of double valve surgery, the increased risk of long-term thrombotic and bleeding complications with multiple mechanical valves, the risk of leaving one valve unoperated and the probability of requiring redo surgery. The role of a multidisciplinary heart valve team is critical in this setting to optimize management and outcomes. The role of transcatheter approaches is currently limited, but technological advances will probably soon change the management paradigm.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Affections valvulaires multiples; Aortic regurgitation; Cardiopathies valvulaires; Heart valve team; Insuffisance aortique; Insuffisance mitrale; Mitral regurgitation; Multiple valve disease

Mesh:

Year:  2019        PMID: 31153874     DOI: 10.1016/j.acvd.2019.04.003

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  3 in total

Review 1.  Serotonin-A Driver of Progressive Heart Valve Disease.

Authors:  Helge Waldum; Alexander Wahba
Journal:  Front Cardiovasc Med       Date:  2022-01-28

Review 2.  Multivalvular Disease: Percutaneous Management in 2019 and Beyond.

Authors:  Magdalena Erlebach; Rüdiger Lange
Journal:  Interv Cardiol       Date:  2019-11-18

3.  Combined Mitral and Aortic Valve Surgery: 17-year Experience in a Single Center.

Authors:  Annastiina Husso; Teemu Riekkinen; Aino Rissanen; Juho Ollila; Antti Valtola
Journal:  Scand J Surg       Date:  2021-01-18       Impact factor: 2.360

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.